Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
18h
Shares of Palatin Technologies, Inc. (PTN) gained 16% on Monday after the company announces completion of patient enrollment in phase ...
KEY POINTS A 72-year-old man presented to the emergency department with a 2-week history of hypotension, postural dizziness, and muscle weakness. He had a medical history of HIV, lipodystrophy, ...
Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial Series A ...
Irish Independent on MSN7h
Patients with severe asthma suffer ‘delayed diagnosis and restricted access to drugs’, report saysA young teacher who suffers from severe asthma has spoken of how patients with the high-risk condition can be left on ...
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...
22h
Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s ...
If you are experiencing hair loss, find a dermatologist who will help you address the various aspects of hair thinning ...
Affected children and young adults should undergo a thorough diagnostic workup, including collection of clinical history, ...
Low anti-TNF levels during infliximab or adalimumab maintenance treatment are linked to increased risk for treatment failure in pediatric CD.
CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback